Cancer is a complex disease where multiple genetic and environmental factors contribute to risk. Its onset and progression depends on the combination of a series of genetic disruptions rather than on ...

The PTEN-PI3K-AKT pathway is among the most frequently dysregulated oncogenic pathways in metastatic castration-resistant prostate cancer (mCRPC). Multiple inhibitors of this pathway are in late-phase ...

ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy A next-generation sequencing–based cfDNA assay was used to profile 231 patients with mCRPC from ...

Truqap with Zytiga and ADT improved radiographic progression-free survival in patients with PTEN-deficient prostate cancer compared to placebo. The CAPitello-281 trial involved 1,012 patients, showing ...

Immunotherapies have been successful in treating many cancer conditions; however, not much success has yet been achieved in metastatic castrate-resistant prostate cancer (mCRPC). A study published ...

A new research paper was published in Genes & Cancer on May 16, 2024, entitled, "Inhibitory effect of miR-377 on the proliferative and invasive behaviors of prostate cancer cells through the ...

A team of researchers from the Badalona Applied Research Group in Oncology (B·ARGO) and the Urologic Tumours Unit of the Institut Català d'Oncologia (ICO) and the Germans Trias i Pujol Research ...

Cancer is very difficult to treat due to various components that therapies must address to effectively kill or lyse tumor cells. There are two general categories of cancer: blood or hematologic ...

ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy A next-generation sequencing–based cfDNA assay was used to profile 231 patients with mCRPC from ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A ...